Moleculin Biotech (NASDAQ:MBRX – Get Free Report) is set to release its earnings data after the market closes on Friday, November 8th. Analysts expect Moleculin Biotech to post earnings of ($2.44) per share for the quarter.
Moleculin Biotech (NASDAQ:MBRX – Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($2.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.10) by ($0.13). On average, analysts expect Moleculin Biotech to post $-9 EPS for the current fiscal year and $-6 EPS for the next fiscal year.
Moleculin Biotech Price Performance
NASDAQ:MBRX opened at $2.36 on Thursday. Moleculin Biotech has a one year low of $2.12 and a one year high of $15.75. The firm has a 50-day moving average of $2.50 and a 200-day moving average of $3.39.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on MBRX
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Further Reading
- Five stocks we like better than Moleculin Biotech
- The Basics of Support and Resistance
- What a Trump Win Looks Like for the Market Now and Into 2025
- What is the FTSE 100 index?
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- Are Penny Stocks a Good Fit for Your Portfolio?
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
